To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantation

Trial Profile

To investigate the efficacy and safety of bortezomib as maintenance therapy for untreated multiple myeloma patients ineligible for autologous stem cell transplantation

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top